Overview

* BeyondSpring ( BYSI ) Q3 net loss narrows to $1.7 mln from $2.2 mln last year

* Plinabulin shows promising results in NSCLC patients at SITC 2025 presentations

* SEED secures $30 mln financing, achieves IND clearance for RBM39 program

Outlook

* BeyondSpring ( BYSI ) emphasizes Plinabulin's potential in resensitizing tumors resistant to checkpoint inhibitors

* Company highlights SEED's IND clearance for RBM39 degrader program in the US and China

* BeyondSpring ( BYSI ) focuses on advancing Plinabulin's clinical development for durable survival benefits

Result Drivers

* Research and development (R&D) expenses were $1.0 million for the quarter ended September 30, 2025 compared to $0.6 million for the quarter ended September 30, 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$1.70

Income mln

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)